| 1.17 0.06 (5.41%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.54 | 1-year : | 1.77 |
| Resists | First : | 1.32 | Second : | 1.51 |
| Pivot price | 1.17  |
|||
| Supports | First : | 1 | Second : | 0.83 |
| MAs | MA(5) : | 1.12 |
MA(20) : | 1.21 |
| MA(100) : | 1.21 |
MA(250) : | 1.57 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 37 |
D(3) : | 21 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 3.53 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BOLD ] has closed above bottom band by 47.4%. Bollinger Bands are 8.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.15 - 1.16 | 1.16 - 1.16 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 1.1 - 1.11 | 1.11 - 1.12 |
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Mon, 24 Nov 2025
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Wed, 05 Nov 2025
Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights - The Manila Times
Wed, 05 Nov 2025
Boundless Bio Inc. Reports Q3 2025 Financial Results - TipRanks
Fri, 24 Oct 2025
H.C. Wainwright reiterates Buy rating on Boundless Bio stock at $4 target - Investing.com
Mon, 13 Oct 2025
Boundless Bio to Present Research on Novel Cancer Therapeutics at AACR-NCI-EORTC Conference 2025 - Quiver Quantitative
Tue, 05 Aug 2025
Boundless Bio (BOLD) Q2 R&D Drops 17% - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 55.2 (%) |
| Shares Short | 40 (K) |
| Shares Short P.Month | 127 (K) |
| EPS | -2.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.7 % |
| Return on Equity (ttm) | -44.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -0.44 |
| PEG Ratio | 0 |
| Price to Book value | 0.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|